8-K: ATAI Amends Beckley Psytech Acquisition Terms

ATAI Life Sciences N.V. has amended its Share Purchase Agreement with Beckley Psytech Limited, reducing the number of shares issued to Beckley Psytech shareholders and allocating shares to Cantor Fitzgerald & Co. for advisory services.

Summary

• The Share Purchase Agreement (SPA) with Beckley Psytech Limited has been amended via a Side Letter Deed, dated October 23, 2025.
• The number of ATAI ordinary shares to be issued to Beckley Psytech shareholders will be reduced on a pro-rata basis by an aggregate of 1,221,712 shares.
• A total of 103,823,190 ATAI shares will now be distributed to shareholders of Beckley Psytech or underlie Replacement Awards for optionholders.
• 900,901 ATAI shares will be issued to Cantor Fitzgerald & Co. (CF&CO) for financial advisory services, with these shares not subject to any lock-up restrictions and registered for resale immediately after closing.
• The definition of 'Permitted Costs' has been revised to adjust the amount of permitted leakage and to include certain payments to CF&CO pursuant to a fee reduction amendment agreement.
• The definition of 'Buyer Share Price' was amended to clarify the calculation period, and 'VWAP' was amended to specify calculation by reference to daily closing price.
• Lock-up provisions for Consideration Shares and Replacement Awards remain in effect, with ATAI having discretion to release up to 0.75% of Consideration Shares for Beckley Optionholders' tax obligations.

Sentiment

Score: 6

Explanation: The amendments clarify the terms of an ongoing acquisition, which is generally positive for transparency and certainty. However, the reduction in shares for target shareholders and the immediate release of shares for advisors could be seen as minor negatives. Overall, it's a procedural update to a significant transaction.

Positives

• The amendments clarify the terms of the ongoing acquisition, providing greater certainty for all parties involved.
• Resolution of certain 'leakages' through a defined share reduction mechanism streamlines the transaction process.
• Compensation for financial advisors (CF&CO) is explicitly detailed, ensuring transparency.

Negatives

• The aggregate number of ATAI shares to be received by Beckley Psytech shareholders is reduced by 1,221,712 shares.
• 900,901 ATAI shares issued to Cantor Fitzgerald & Co. will not be subject to lock-up restrictions, potentially increasing immediate market float.

Risks

• The Proposed Transactions (acquisition and redomiciliation) may not be completed in a timely manner or at all, including the risk that required shareholder approvals are not obtained.
• Failure to realize the anticipated benefits of the Proposed Transactions.
• Any or all of the various conditions to the consummation of the Proposed Transactions may not be satisfied or, in the case of the acquisition of Beckley Psytech, waived.
• The occurrence of any event, change, or other circumstance that could give rise to the termination of the share purchase agreement.
• The effects of the redomiciliation transaction on trading, liquidity, and the price of ATAI securities.
• The effect of the announcement or pendency of the Proposed Transactions on ATAI's ability to retain and hire key personnel, or its operating results and business generally.

Future Outlook

The filing contains forward-looking statements regarding the closing of the acquisition of Beckley Psytech Limited and the redomiciliation transaction, including timing, terms, approvals, and expectations for the combined company's operations. It also references the public announcement of results of Beckley Psytech's Phase 2b Clinical Trial for BPL-003 as a trigger for the expiration of certain lock-up provisions.

Industry Context

na

Stakeholder Impact

• Shareholders of Beckley Psytech: Will receive 1,221,712 fewer ATAI shares in aggregate than initially planned, but the transaction proceeds with clarified terms.
• Optionholders of Beckley Psytech: Will receive Replacement Awards or Consideration Shares, subject to lock-up provisions, with a potential release of up to 0.75% for tax obligations.
• Cantor Fitzgerald & Co. (CF&CO): Will receive 900,901 ATAI shares for advisory services, which are not subject to lock-up restrictions, allowing for immediate resale.
• ATAI Life Sciences N.V. Shareholders: The overall acquisition terms are being refined, providing more clarity on the share consideration and associated costs for a material transaction.

Next Steps

• Shareholders must notify ATAI of their intention to attend the Extraordinary General Meeting by October 31, 2025.
• The Extraordinary General Meeting will be held to adopt Shareholder Approval for the Proposed Transactions.
• A prospectus supplement will be filed by ATAI immediately following the closing of the transaction to register CF&CO's shares for resale.
• The acquisition of Beckley Psytech is expected to close, subject to conditions.
• Replacement Awards will be granted to Beckley Optionholders within five business days of Closing.
• The public announcement of the results of Beckley Psytech's Phase 2b Clinical Trial for BPL-003 will trigger the expiration of certain lock-up restrictions.

Key Dates

Recommendation

The filing details procedural amendments to an ongoing acquisition, clarifying share allocations and financial advisor compensation. While the reduction in shares for Beckley Psytech shareholders and the immediate liquidity for Cantor Fitzgerald & Co. are notable, these are adjustments within a larger, previously announced transaction. The core strategic rationale for the acquisition remains unchanged by these amendments. Investors should hold to observe the successful completion of the acquisition and subsequent integration, as well as the progress of Beckley Psytech's clinical trials, which are more significant drivers for long-term value.

Keywords

ATAI Life Sciences, Beckley Psytech, Share Purchase Agreement, Acquisition Amendment, Cantor Fitzgerald, SEC Filing, 8-K, Corporate Governance, Shareholder Approval, Lock-up, Consideration Shares, BPL-003